Respiratory Infections News

Researchers demonstrated how a “breathalyzer” test could be developed to detect SARS-CoV-2 infection in children.

The FDA has issued the first emergency use authorization for an over-the-counter home diagnostic test for COVID-19.

Throughout the COVID-19 pandemic, close contact among people in Hong Kong was reduced by 59%, according to mass transit and survey data published in Clinical Infectious Diseases.

A risk score based on patient comorbidities, obesity, vital signs, age and sex accurately predicted death or respiratory decompensation within 7 days among patients with pneumonia, suspected COVID-19 or confirmed COVID-19, data show.

In less than a year, scientists were able to develop several efficacious COVID-19 vaccine candidates — one of which was authorized for emergency use by the FDA late Friday after an advisory panel of experts backed its use.

About one-third of children who tested positive for SARS-CoV-2 were asymptomatic, an observational study in Canada showed.

In a new modeling study, researchers estimated that nearly 53 million SARS-CoV-2 infections — including 2.4 million associated hospitalizations — may have occurred in the United States through September 30.

Data from the Colorado Immunization Information System showed a decrease in vaccination adherence among three separate age groups as a result of the pandemic.

The California Department of Public Health “strongly recommends” that as of next Monday, general acute care hospitals in the state begin weekly testing of all health care professionals for COVID-19.

An FDA advisory committee voted 17 to 4, with one abstention, in favor of granting an emergency use authorization, or EUA, for Pfizer and BioNTech’s COVID-19 vaccine candidate for individuals aged 16 years and older.